PRNewswire

Restructuring to Optimize Real Estate Footprint and Facilitate Going Concern Sale

ORLANDO, Fla., May 19, 2024 /PRNewswire/ -- Red Lobster Management LLC, along with its direct and indirect operating subsidiaries ("Red Lobster" or "the Company"), owner and operator of the Red Lobster® restaurant chain, today announced that the Company has voluntarily filed for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the Middle District... (continue reading...)

SINGAPORE, May 19, 2024 /PRNewswire/ -- OKX, a leading crypto exchange and Web3 technology company, today announced a strategic partnership with Hidden Road Partners (Hidden Road), the global credit network for institutions. This partnership aims to offer a turn-key experience for Hidden Road's clients, enabling them to execute advanced trading strategies and facilitate delta rolls more efficiently.

... (continue reading...)

SJMC's significant efforts in alleviating nursing shortages, enhancing workflows and its strong market-leading position, both locally and globally resulted in high patient retention and strong referrals.

SAN ANTONIO, May 19, 2024 /PRNewswire/ -- Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare... (continue reading...)

TOKYO, May 19, 2024 /PRNewswire/ -- TIER IV, a pioneer in developing open-source software for autonomous driving (AD) systems, is set to launch a unique robotaxi service in November 2024. Initially targeting areas and times that conventional taxi operators struggle to serve, the service will begin with proof of concept (PoC) tests in the Tokyo Bay area of Odaiba. The goal is to gradually expand to cover major districts in Tokyo by 2025 and the entire metropolitan area... (continue reading...)

SAN FRANCISCO and SUZHOU, China, May 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the company will deliver oral presentations on clinical data of its first-in-class PD-1/IL-2 bispecific antibody... (continue reading...)